Teneobio, Inc. has entered into a research collaboration and licensing agreement with TESARO, Inc. to develop novel multi-specific antibodies for up to six undisclosed oncology targets. 

Under the terms of the agreement, Teneobio will generate product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.  

Teneobio will receive an upfront of $10 million and is eligible for research fees and up to $50M in development milestones per product. They can also receive royalties on world–wide net sales of each multi-specific product. 

Roland Buelow, chief executive officer of Teneobio, added, “We are excited to embark on a productive research collaboration with TESARO. Complementing our internal pipeline, our strategic alliance with TESARO further leverages the bandwidth and efficiency of Teneobio’s state-of-the-art discovery platforms to advance specific biotherapeutics to the clinic.”